Trifluridine–tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study

Details 詳細情報について

• CRID

  1360861711778614912

• DOI

  10.1016/s2468-1253(22)00334-x

• ISSN

  24681253

• Web Site

  https://api.elsevier.com/content/article/PII:S246812532200334X?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S246812532200334X?httpAccept=text/plain

• Data Source

  • Crossref